Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
170.3 USD | -0.97% | +1.81% | -21.53% |
20/03 | US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady | MT |
20/03 | Insulet Names Ana Maria Chadwick Finance Chief | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 57.83 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.53% | 11.92B | B- | ||
-3.43% | 184B | C+ | ||
-1.81% | 107B | C | ||
-4.15% | 67.52B | A | ||
+1.43% | 50.06B | B- | ||
+11.60% | 45.67B | B- | ||
+3.40% | 41B | B+ | ||
+3.03% | 26.73B | B | ||
+3.21% | 26.47B | A- | ||
+15.23% | 25.05B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PODD Stock
- Ratings Insulet Corporation